Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMDex vs MDex in untreated systemic AL amyloidosis
NCT01078454Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of bortezomib in light-chain amyloidosis, sponsored by National Cancer Institute. Started Nov 2010; status: completed.
02
Drugs
bortezomib
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT01078454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01078454.